MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 89 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,073,327 | -25.9% | 1,872,463 | 0.0% | 3.72% | -10.0% |
| Q2 2023 | $20,334,948 | +57.4% | 1,872,463 | 0.0% | 4.13% | +49.7% |
| Q1 2023 | $12,919,995 | +73.4% | 1,872,463 | 0.0% | 2.76% | +70.1% |
| Q4 2022 | $7,452,403 | -15.3% | 1,872,463 | +41.6% | 1.62% | -11.7% |
| Q3 2022 | $8,794,000 | +37.4% | 1,322,463 | 0.0% | 1.84% | +38.8% |
| Q2 2022 | $6,401,000 | -48.2% | 1,322,463 | 0.0% | 1.32% | -39.7% |
| Q1 2022 | $12,365,000 | -2.0% | 1,322,463 | +24.5% | 2.19% | +11.4% |
| Q4 2021 | $12,623,000 | +4.4% | 1,062,500 | 0.0% | 1.97% | +0.3% |
| Q3 2021 | $12,091,000 | -36.6% | 1,062,500 | 0.0% | 1.96% | -31.7% |
| Q2 2021 | $19,061,000 | -25.8% | 1,062,500 | -36.0% | 2.88% | +31.1% |
| Q1 2021 | $25,694,000 | +195.6% | 1,659,820 | +133.0% | 2.19% | +29.6% |
| Q4 2020 | $8,692,000 | +16.5% | 712,500 | +22.7% | 1.69% | +26.7% |
| Q3 2020 | $7,459,000 | – | 580,462 | – | 1.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |